The First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
J Int Med Res. 2022 Feb;50(2):3000605221081672. doi: 10.1177/03000605221081672.
Lung adenocarcinoma is one of the most common solid tumors, and diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of adult non-Hodgkin's lymphoma. Although extra-nodular lesions are frequently observed in patients with DLBCL, urinary bladder involvement is rare. We report the case of a 77-year-old woman with lung adenocarcinoma who was diagnosed with a second primary bladder DLBCL, 9 months after treatment with molecular targeted drugs. Simultaneous therapies for her lymphoma with lenalidomide and rituximab and a tyrosine kinase inhibitor therapy for her lung cancer were both effective. This result was consistent with previous reports suggesting that patients unable to tolerate intensive chemotherapy could benefit from targeted therapies. Current research into the use of lenalidomide for the treatment of lymphomas and solid tumors is promising in terms of exploring immunotherapy as an alternative option for patients with concurrent solid tumors and lymphomas who have poor tolerance to radiotherapy and chemotherapy.
肺腺癌是最常见的实体肿瘤之一，弥漫性大 B 细胞淋巴瘤（DLBCL）是成人非霍奇金淋巴瘤最常见的组织学亚型。尽管在 DLBCL 患者中经常观察到结节外病变，但膀胱受累很少见。我们报告了一例 77 岁女性肺腺癌患者的病例，该患者在接受分子靶向药物治疗 9 个月后被诊断出患有第二原发性膀胱 DLBCL。同时对她的淋巴瘤进行来那度胺和利妥昔单抗治疗，以及对她的肺癌进行酪氨酸激酶抑制剂治疗，均取得了疗效。这一结果与之前的报告一致，即不能耐受强化化疗的患者可能受益于靶向治疗。目前对来那度胺治疗淋巴瘤和实体瘤的研究有希望探索免疫疗法作为对放疗和化疗耐受性差的同时患有实体瘤和淋巴瘤的患者的替代选择。
